News AZ, Amgen positive Ph3 results for Tezspire in EoE AstraZeneca and Amgen have announced the first Phase III results for Tezspire (tezepelumab) in eosinophilic oesophagitis (EoE).
News Amgen and UCB re-file Evenity for US approval Amgen and UCB have resubmitted their application for US approval of Evenity as an osteoporosis treatment, hoping that the additional data they have provided will help overcome the FDA’s pre
News Avacta hoping to disrupt antibody drug dominance Avacta is one of several biotechs turning their backs on mabs.
R&D Boosting biotech in Basel – with Valentina Francia pharmaphorum speaks with Valentina Francia from Basel Area Business and Innovation about why many life sciences startups are finding success in Basel.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
